These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 30596091)

  • 1. Natural Compounds for the Management of Parkinson's Disease and Attention-Deficit/Hyperactivity Disorder.
    Corona JC
    Biomed Res Int; 2018; 2018():4067597. PubMed ID: 30596091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in discovery and development of natural products as source for anti-Parkinson's disease lead compounds.
    Zhang H; Bai L; He J; Zhong L; Duan X; Ouyang L; Zhu Y; Wang T; Zhang Y; Shi J
    Eur J Med Chem; 2017 Dec; 141():257-272. PubMed ID: 29031072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amelioration of Mitochondrial Quality Control and Proteostasis by Natural Compounds in Parkinson's Disease Models.
    Cho B; Kim T; Huh YJ; Lee J; Lee YI
    Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31640129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Do prescription stimulants increase risk of Parkinson's disease among adults with attention-deficit hyperactivity disorder? A retrospective cohort study.
    Kindt HM; Tuan WJ; Bone CW
    Fam Pract; 2024 Aug; 41(4):605-609. PubMed ID: 36593727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Collicular dysfunction in attention deficit hyperactivity disorder.
    Overton PG
    Med Hypotheses; 2008; 70(6):1121-7. PubMed ID: 18215471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The dopaminergic hypothesis of attention-deficit/hyperactivity disorder needs re-examining.
    Gonon F
    Trends Neurosci; 2009 Jan; 32(1):2-8. PubMed ID: 18986716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of executive function in ADHD.
    Swanson JM
    J Clin Psychiatry; 2003; 64 Suppl 14():35-9. PubMed ID: 14658934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the dopamine system in the treatment of attention-deficit/hyperactivity disorder.
    Staller JA; Faraone SV
    Expert Rev Neurother; 2007 Apr; 7(4):351-62. PubMed ID: 17425490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current drug therapy recommendations for the treatment of attention deficit hyperactivity disorder.
    Cyr M; Brown CS
    Drugs; 1998 Aug; 56(2):215-23. PubMed ID: 9711446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Immunological and endocrinological pattern in ADHD etiopathogenesis].
    Budziszewska B; Basta-Kaim A; Kubera M; Lasoń W
    Przegl Lek; 2010; 67(11):1200-4. PubMed ID: 21442976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Attention-Deficit/Hyperactivity Disorder.
    Bokor G; Anderson PD
    J Pharm Pract; 2014 Aug; 27(4):336-49. PubMed ID: 25092688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Depressive symptoms as a side effect of the sustained release form of methylphenidate in a 7-year-old boy with attention-deficit hyperactivity disorder.
    Lakić A
    Vojnosanit Pregl; 2012 Feb; 69(2):201-4. PubMed ID: 22500377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vitamin D's Molecular Action Mechanism in Attention-Deficit/ Hyperactivity Disorder: A Review of Evidence.
    Saedisomeolia A; Samadi M; Gholami F; Seyedi M; Effatpanah M; Hashemi R; Abdolahi M; Honarvar NM
    CNS Neurol Disord Drug Targets; 2018; 17(4):280-290. PubMed ID: 29714151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is the treatment with psychostimulants in children and adolescents with attention deficit hyperactivity disorder harmful for the dopaminergic system?
    Gerlach M; Grünblatt E; Lange KW
    Atten Defic Hyperact Disord; 2013 Jun; 5(2):71-81. PubMed ID: 23605387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Medicinal Chemistry of Natural and Semisynthetic Compounds against Parkinson's and Huntington's Diseases.
    Zanforlin E; Zagotto G; Ribaudo G
    ACS Chem Neurosci; 2017 Nov; 8(11):2356-2368. PubMed ID: 28862431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antioxidant therapies in attention deficit hyperactivity disorder.
    Moghadas M; Essa MM; Ba-Omar T; Al-Shehi A; Qoronfleh MW; Eltayeb EA; Guillemin GJ; Manivasagam T; Justin-Thenmozhi A; Al-Bulushi BS; Al-Adawi S; Edalatmanesh MA
    Front Biosci (Landmark Ed); 2019 Jan; 24(2):313-333. PubMed ID: 30468658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toward a pathophysiology of attention-deficit/hyperactivity disorder.
    Castellanos FX
    Clin Pediatr (Phila); 1997 Jul; 36(7):381-93. PubMed ID: 9241475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inattention and hyperactivity/impulsivity among children with attention-deficit/hyperactivity-disorder, autism spectrum disorder, and intellectual disability.
    McClain MB; Hasty Mills AM; Murphy LE
    Res Dev Disabil; 2017 Nov; 70():175-184. PubMed ID: 28957735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysis. Part 1: psychostimulants, alpha-2 agonists, and atomoxetine.
    Pringsheim T; Hirsch L; Gardner D; Gorman DA
    Can J Psychiatry; 2015 Feb; 60(2):42-51. PubMed ID: 25886655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parkinson's Disease: A Current Perspectives on Parkinson's Disease and Key Bioactive Natural Compounds as Future Potential Drug Candidates.
    Ali N; Syeda A; Topgyal T; Gaur N; Islam A
    Curr Drug Targets; 2022; 23(1):2-20. PubMed ID: 34165406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.